Advanced search
Publication Cover
Expert Review of Clinical Pharmacology Volume 12, 2019 - Issue 2
Submit an article Journal homepage
297
Views
3
CrossRef citations to date
0
Altmetric
Letter to the Editor

Response letter to ‘does high LDL-cholesterol cause cardiovascular disease?’

Uffe RavnskovIndependent Investigator, Lund, SwedenCorrespondence[email protected]
View further author information
,
Michel De LorgerilLaboratoire Coeur et Nutrition, TIMC-IMAG, School of Medicine, University of Grenoble-Alpes, Grenoble, FranceView further author information
,
David M. DiamondDepartment of Psychology, Center for Preclinical and Clinical Research on PTSD, University of South Florida, Tampa, FL, USA;Department of Molecular Pharmacology and Physiology, Center for Preclinical and Clinical Research on PTSD, University of South Florida, Tampa, FL, USAView further author information
,
Rokuro HamaNPO Japan Institute of Pharmacovigilance, Osaka, JapanView further author information
,
Tomohito HamazakiDepartment of Internal Medicine, Toyama Jonan Onsen Daini Hospital, University of Toyama, Toyama, JapanView further author information
,
Björn HammarskjöldStrömstad Academy, Strömstad, SwedenView further author information
,
Niamh HynesWestern Vascular Institute, University Hospital Galway & Galway Clinic, National University of Ireland & Royal college of Surgeons of Ireland affiliated Hospital, Galway, IrelandView further author information
,
Malcolm KendrickEast Cheshire Trust, Macclesfield District General Hospital, Macclesfield, EnglandView further author information
,
Peter H LangsjoenPrivate Practice in Cardiology, Tyler, TX, USAView further author information
,
Luca MascitelliMedical Officer Service, Comando Brigata Alpina “Julia”/Multinational Land Force, Udine, ItalyView further author information
,
Kilmer S. McCullyPathology and Laboratory Medicine Service, VA Boston Healthcare System, West Roxbury; Harvard Medical School, Boston, MA, USAView further author information
,
Harumi OkuyamaNagoya City University, Mizuhoku, Nagoya, JapanView further author information
,
Paul J. RoschNew York Medical College, The American Institute of Stress, New York, NY, USAView further author information
,
Tore ScherstenWallenberg Laboratory for Cardiovascluar and Metabolic Research, Sahlgren’s Academy, University of Gothenburg, Gothenburg, Sweden, and Columbia University, NY, USAView further author information
,
Sherif SultanWestern Vascular Institute, University Hospital Galway & Galway Clinic, National University of Ireland & Royal college of Surgeons of Ireland affiliated Hospital, Galway, IrelandView further author information
&
Ralf SundbergOdenvägen 44B, Lidingö, SwedenView further author information
 show all
Pages 93-94 | Received 27 Jul 2018, Accepted 14 Dec 2018, Published online: 16 Jan 2019

References

  • Uusitupa MI, Niskanen LK, Siitonen O, et al. 5-year incidence of atherosclerotic vascular disease in relation to general risk factors, insulin level, and abnormalities in lipoprotein composition in non-insulin-dependent diabetic and nondiabetic subjects. Circulation. 1990;82:27–36.
  • Jarrett RJ. Risk factors for coronary heart disease in diabetes mellitus. Diabetes. 1992;41(Suppl 2):1–3.
  • Laakso M, Lehto S, Penttilä I, et al. Lipids and lipoproteins predicting coronary heart disease mortality and morbidity in patients with non-insulin-dependent diabetes. Circulation. 1993;88:1421–1430.
  • Simons LA, McCallum J, Friedlander Y, et al. Diabetes, mortality and coronary heart disease in the prospective Dubbo study of Australian elderly. Aust N Z J Med. 1996;26:66–74.
  • Niskanen L, Turpeinen A, Penttilä I, et al. Hyperglycemia and compositional lipoprotein abnormalities as predictors of cardiovascular mortality in type 2 diabetes: a 15-year follow-up from the time of diagnosis. Diabetes Care. 1998;21:1861–1869.
  • Östgren CJ, Lindblad U, Melander A, et al. Survival in patients with type 2 diabetes in a Swedish community: skaraborg hypertension and diabetes project. Diabetes Care. 2002;25:1297–1302.
  • Solfrizzi V, Panza F, Colacicco AM, et al. Relation of lipoprotein(a) as coronary risk factor to type 2 diabetes mellitus and low-density lipoprotein cholesterol in patients > or =65 years of age (the Italian longitudinal study on aging). Am J Cardiol. 2002;89:825–829.
  • Roselli Della Rovere G, Lapolla A, Sartore G, et al. Plasma lipoproteins, apoproteins and cardiovascular disease in type 2 diabetic patients. A nine-year follow-up study. Nutr Metab Cardiovasc Dis. 2003;13:46–51.
  • Liu J, Sempos C, Donahue RP, et al. Joint distribution of non-HDL and LDL cholesterol and coronary heart disease risk prediction among individuals wal.ith and without diabetes. Diabetes Care. 2005;28:1916–1921.
  • Zoppini G, Targher G, Negri C, et al. Usefulness of the triglyceride to high-density lipoprotein cholesterol ratio for predicting mortality risk in type 2 diabetes: role of kidney dysfunction. Atherosclerosis. 2010;212:287–291.
  • Hero C, Svensson AM, Gidlund P, et al. LDL cholesterol is not a good marker of cardiovascular risk in type 1 diabetes. Diabet Med. 2016;33:316–323.
  • Sharif S, van der Graaf Y, Nathoe HM, et al. HDL cholesterol as a residual risk factor for vascular events and all-cause mortality in patients with type 2 diabetes. Diabetes Care. 2016;39:1424–1430.
  • Feng Q, Wei WQ, Chung CP, et al. Relationship between very low low-density lipoprotein cholesterol concentrations not due to statin therapy and risk of type 2 diabetes: A US-based cross-sectional observational study using electronic health records. PLoS Med. 2018;15:e1002642.
  • de Lorgeril M, Hamazaki T, Kostucki W, et al. Is the use of cholesterol-lowering drugs for the prevention of cardiovascular complications in type 2 diabetics evidence-based? A systematic review. Rev Recent Clin Trials. 2012;7:150–157.
  • Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–2207.
  • Cederberg H, Stančáková A, Yaluri N, et al. Increased risk of diabetes with statin treatment is associated with impaired insulin sensitivity and insulin secretion: a 6 year follow-up study of the METSIM cohort. Diabetologia. 2015;58:1109–1117.
  • Cai R, Yuan Y, Zhou Y, et al. Lower intensified target LDL-C level of statin therapy results in a higher risk of incident diabetes: a meta-analysis. PLoS One. 2014;9:e104922. eCollection 2014.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.